Escolar Documentos
Profissional Documentos
Cultura Documentos
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, United States
Pharmaceutical and Analytical Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, United States
a r t i c l e
i n f o
Article history:
Received 19 August 2012
Received in revised form 2 December 2012
Accepted 4 December 2012
Available online 13 December 2012
Keywords:
Solid lipid nanoparticles
Nanostructured lipid carriers
Sonication
Physical stability
Solid lipid
Oleic acid
a b s t r a c t
The main objective of this study was to evaluate the potential of lipid nanosystems for topical delivery of
the naturally occurring avonoid quercetin. These lipid based nanosystems were manufactured using a
solvent free probe ultrasonication process. Formulation factors such as the nature of the lipid (solid/combination of solid and liquid) in solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) systems and drug loading were evaluated to produce an optimum formulation with adequate physical
stability for up to 14 weeks at 28 C. The mean particle size of the optimized formulation was around
282 nm, with a zeta potential value of 36.57 2.67 mV, indicating the formation of a stable system.
Release studies showed a biphasic release prole, characterized by an initial burst release followed by
a more controlled release pattern from both SLN and NLC systems. The NLC system showed the highest
improvement in topical delivery of quercetin manifested by the amount of quercetin retained in full
thickness human skin, compared to a control formulation with similar composition and particle size in
the micrometer range. This study demonstrated the feasibility of nanostructured lipid carrier systems
for improved topical delivery of quercetin.
2012 Elsevier B.V. All rights reserved.
1. Introduction
Excessive exposure of the skin to environmental insults including sun and air pollution can lead to oxidative stress (OS) to the
skin. Under these conditions, reactive oxygen species (ROS) such
as singlet oxygen, hydroxyl radicals, superoxide radical-anions
and hydrogen peroxide can be generated by the photodynamic
reactions produced by endogenous cell photosensitizers. These
reactive oxygen species are capable of causing damage to cutaneous tissues (Pourzand and Tyrrell, 1999). They have also been reported to be involved in phototoxic reactions induced by the
interaction of UVA/visible light with drugs or chemical entities
(environmental or industrial) accumulated in the skin following
topical or systemic administration (Epstein, 1983). The use of topical antioxidants has been evaluated as a promising strategy for
prevention or alleviation of the biological effects of photo-oxidative stress produced in the skin by ROS.
Flavonoids are natural antioxidants derived from the plant
kingdom and are widely present in the human diet in the form of
numerous edible fruits and vegetables such as onions, apples, ber Corresponding author. Current address: Department of Pharmaceutics, 160
Frelinghuysen Road, Piscataway, NJ 08854, United States. Tel.: +1 732 445 3589;
fax: +1 732 445 5006.
E-mail address: michniak@biology.rutgers.edu (B. Michniak-Kohn).
0928-0987/$ - see front matter 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.ejps.2012.12.005
443
solvent based manufacturing method could be the failure to completely eliminate residual solvent (Grabnar and Kristl, 2011). The
objective of our study was to develop a solvent-free NLC formulation of quercetin using probe ultrasonication and evaluate its feasibility for topical delivery. The NLC system was fully
characterized for particle size, zeta potential, morphology and
crystallinity. Key properties such as physical/solid state stability
and in vitro drug release, that could affect formulation performance
in vivo, were compared between the two systems.
1975). This limits the extension of the benecial effects of quercetin observed in in vitro studies to the in vivo or clinical level with an
oral delivery approach. Hence topical application of quercetin can
be a very attractive formulation approach, considering the fact that
topical application of quercetin has previously been shown to result in potent inhibition of UVB-induced oxidative skin damage
(Casagrande et al., 2006; Gonzalez et al., 2008).
Various formulation approaches including permeation enhancers (Olivella et al., 2007), ester based prodrugs (Montenegro
et al., 2007), microemulsion based approaches (Vicentini et al.,
2008; Kitagawa et al., 2009) and lecithinchitosan nanoparticles
(Tan et al., 2011) have been attempted to improve the penetration
of quercetin through the skin to facilitate topical/transdermal
delivery. Most of these studies have shown some degree of quercetin penetration into the skin, but no transdermal delivery has been
reported. However, since the efcacy of quercetin in delaying ultra-violet radiation mediated cell damage and eventual necrosis
mainly occurs in the epidermal layers of the skin, topical delivery
of quercetin without a sufcient degree of skin penetration should
be adequate to achieve the desired pharmacological action.
Lipid based nanosystems such as solid lipid nanoparticles
(SLNs) and nanostructured lipid carriers (NLCs) have been previously shown to improve the delivery of various actives such as glucocorticoids (Maia et al., 2000; Jensen et al., 2011), Vitamin A
(Jenning et al., 2000c) and betamethasone 17-valerate (Zhang
and Smith, 2011) to specic skin layers, with reported localization
in the upper layers of the skin. Such a formulation approach has
also been utilized by our group to develop solid lipid based nanosystems of quercetin and evaluate their feasibility for topical delivery using full thickness human skin (Bose et al., submitted for
publication). The optimized SLN formulation showed superior topical delivery of quercetin compared to the control formulation with
particle size in the micrometer range, with the differences being
statistically signicant (p < 0.05). However, an increase in the particle size was observed for samples placed on stability at 28 C
after 8 weeks. This increase in particle size could be attributed to
some degree of lipid transformation of the solid lipid (glyceryl
dibehenate) used in these nanoparticles over time, leading to the
formation of a highly ordered lipid structure resulting in drug
expulsion from the SLN system (Muller et al., 2002). The lipid
transformation was conrmed from the morphology of the nanoparticles visualized using TEM and also from X-ray diffraction
patterns.
Nanostructured lipid carriers (NLCs) are a second generation of
lipid based nanoparticles that are obtained by substituting a part of
the solid lipid used in the SLN formulation with a liquid lipid, in order to reduce the rigidity and ordered structure of the lipid matrix
and introduce imperfections in the matrix to minimize drug expulsion upon storage (Muller et al., 2002). Recently, the development
of NLCs of quercetin for topical delivery have been reported using a
solvent (chloroform/acetone) based emulsication technique
(Chen-yu et al., 2012). One of the major difculties of an organic
Highly pure (>99%) quercetin was obtained from Merck (Darmstadt, Germany). Compritol 888 (glyceryl dibehenate) was kindly
donated by Gattefoss (Paramus, NJ, USA). Tween 20 (polyoxyethylene derivative of sorbitan monolaurate), dioctyl sodium sulfosuccinate (DOSS) and oleic acid were purchased from SigmaAldrich
Corporation (St. Louis, MO, USA). HPLC or analytical grade of all
other solvents and reagents were used.
2.2. Preparation of nanosystems of quercetin
Nanostructured lipid carrier (NLC) systems of quercetin were
prepared using probe ultrasonication by melting 0.45 g of the solid
lipid (Compritol 888, glyceryl dibehenate) with 0.05 g of the liquid lipid (oleic acid) and either 0.025 g or 0.0125 g of quercetin
(corresponding to 0.05% or 0.025% drug loading in the system
respectively) at 85 C using a water bath. The heated mixture of
lipids and quercetin was then mixed with 20 mL of surfactant solution (composed of 2.5% Tween 20 and 0.1% DOSS) pre-heated to the
same temperature of 85 C. The mixture was then ultra-sonicated
at 85 C at a specic speed (power setting of four) for a pre-determined time interval (either 5 min or 30 min) using a Sonic Dismembrator Model 550 (Fisher Scientic, Pittsburgh, PA). The
primary product at the end of the sonication step was a nanoemulsion, since the processing temperature of 85 C was at least 10 C
higher than the melting point of the solid lipid and adequate to
maintain the system in the liquid state. At the end of the sonication
process, the nanoemulsion was dispersed into 30 mL of an ice-cold
surfactant solution maintained in an ice bath. The nal mixture
was then ultra-sonicated at a specic speed (power setting of 1)
for 10 min immersed in the ice-bath to promote the formation of
the solid lipid nanoparticles. The corresponding solid lipid nanoparticle (SLN) formulation was prepared in exactly the same way,
using 0.5 g of only the solid lipid (Compritol 888, glyceryl dibehenate) in the composition. All formulations were stored in the
refrigerator at 28 C till further analysis.
The non-homogenized control (for both SLN and NLC) formulation used in the skin penetration experiments were prepared by
mixing the lipid and quercetin solution heated to 85 C with the
surfactant solution heated to the same temperature. No ultrasonication step was performed on these non-homogenized control
formulations.
2.3. Freeze drying of nanoparticles
Samples of quercetin nanoparticles were freeze dried using a
Usifroid Freeze Dryer (Elancourt, France). A cooling rate of 1 C/
min was used to pre-cool the sample from room temperature to
50 C. The sample was then maintained at 50 C for 1 h, followed by primary and secondary drying steps as specied in
Table 1. Since the primary purpose of drying the nanoparticles
was to obtain a powder for further solid state characterization to
444
Table 1
Parameters used for freeze-drying experiments.
Temperature range
1
1
1
1
1
5
480
480
360
360
1
1
1
1
1
600
600
480
720
960
evaluate crystallinity, no matrix formers were added to the solution prior to freeze drying.
2.4. Characterization of nanoparticles
2.4.1. Particle size measurement
The particle size of NLC systems was measured using photon
correlation spectroscopy (PCS) on a Delsa Nano C particle size
analyzer (Beckman Coulter, Brea, CA, USA) at 25 C and at a light
scattering angle of 90. The sample (undiluted) was poured into a
disposable plastic cuvette, the cuvette manually shaken for about
10 s and then placed inside the sample holder of the instrument.
Once the intensity of the sample was within the range recommended by the instrument, analysis was performed to obtain the
particle size and the polydispersity index (PI). All measurements
were performed in triplicate. All reported particle size data refer
to intensity weighted distributions.
2.4.2. Zeta potential measurement
The surface charge on the nanoparticles was quantied by measuring the zeta potential using a Delsa Nano C (Beckman Coulter,
Brea, CA, USA). An appropriately diluted nanoparticle solution was
used for the measurement, under an applied electric eld of 16 V/
cm. Dilutions were performed with distilled water adjusted to a
conductivity of 50 lS/cm by addition of 0.9% (m/v) sodium chloride. All reported values are the mean of three separate
measurements.
2.4.3. Morphology
Transmission electron microscopy (TEM) was used to conrm
the morphology of the nanoparticles using a FEI Tecnai G2 BioTwin
transmission electron microscope tted with a SIS Morada digital
camera system (Fei Corporation, Hillsboro, OR, USA). Formvar
coated copper grids (200 mesh) were oated on top of 510 lL of
liquid sample for approximately 30 min, then rinsed with ltered
HPLC grade water and allowed to dry at room temperature. Images
were captured at magnications ranging from 4800 to 150,000.
PBS solution (pH 7.4) containing 1% Tween 20 maintained at a temperature of 37 0.1 C and a stirring speed of 600 RPM was used as
the receptor medium. 0.5 mL of formulation (NLC or control) was
added to the donor compartment and occluded with Paralm to
prevent evaporation. For the preliminary experiments, 300 lL of
sample was withdrawn at pre-determined time intervals (2, 4, 6,
8 and 24 h) from the receptor compartment and replaced by an
equal volume of fresh receptor media maintained at 37 C. The
samples were stored in the refrigerator prior to HPLC analysis.
At the end of the experiment (24 h), a glass transfer pipette was
used to remove the formulation from the donor compartment. The
surface of the skin was thoroughly washed with distilled water to
remove any excess formulation (Tan et al., 2011) and allowed to
dry at ambient temperature. The area of the skin in contact with
the formulation (corresponding to the diffusion area of the Franz
cell) was then punched out, weighed accurately and cut into ne
pieces. 1 mL of methanol was added to the skin pieces and homogenized using a Polytron PT 1035 homogenizer (Kinematica, Inc.,
Bohemia, NY, USA). The homogenized residue was sonicated for
60 min at 37 C using a VWR Ultrasonic B5500A-DTH sonicator
(VWR International, LLC, Radnor, PA, USA), followed by centrifugation at 4000 RPM for 30 min using an AllegraTM 6R centrifuge
(Beckman Coulter, Brea, CA, USA). The supernatant obtained after
centrifugation was collected and analyzed using the HPLC method
described in Section 2.4.7, with an increased injection volume of
50 lL.
445
446
Fig. 2. Effect of sonication time on physical stability of quercetin NLC systems (n = 3 measurements); PI refers to the polydispersity index.
Fig. 3. Effect of oleic acid on physical stability of quercetin lipid based nanosystems (n = 3 measurements); PI refers to the polydispersity index.
oleic acid (10%) used in the formulation. This is consistent with reports in the literature where no signicant difference in initial particle size (volume average diameter) was observed between NileRed loaded SLN and NLC formulations containing 515% of oleic
acid. Signicant reduction in particle size was only observed when
the amount of oleic acid in the formulation was increased to 30% or
higher, which was attributed to the reduced viscosity of the NLC
system at higher concentrations of oleic acid which facilitated
the reduction of surface tension to generate smaller particles (Hu
et al., 2005). Teeranachaideekul et al. (2007) reported increase in
oil content to have no effect on the initial particle size of Q10loaded NLC systems. Other researchers (Ying et al., 2008; You
et al., 2007) have also reported no signicant effect of oleic acid
on NLC particle size, at low oil concentrations (up to 10% w/w).
In our study, higher concentrations (greater than 10%) of the liquid lipid (oleic acid) were not investigated since an increase in the
concentration of the liquid lipid has been associated with a reduction in the occlusion factor (Teeranachaideekul et al., 2008), which
is one of the major aspects of topical application of lipid based
nanosystems. Also, higher concentrations of oleic acid in NLC systems were not evaluated since the acidic nature of fatty acids have
been associated with dermal side effects including extraction of
the stratum corneum lipids and damage to viable epidermal cells
(Sintov et al., 1999; Touitou et al., 2002). However, the use of oleic
acid in concentrations of up to 10% in topical formulations have
been reported to have no irritating effects on the skin of animal
species such as guinea pigs (Yu et al., 2010) or rabbits (Moreira
et al., 2010).
447
Fig. 4. Effect of drug loading on the physical stability of quercetin NLC systems (n = 3 measurements).
with 0.025% drug loading was also analyzed for quercetin content.
98% of quercetin could be recovered from the formulation. This
indicated that the manufacturing temperature did not induce any
degradation of quercetin and conrmed the validity of the production process.
448
Table 2
Mean particle size and zeta potential of selected NLC formulation upon stability.
Time point
PIa
Initial
8 weeks, 28 C
14 weeks, 28 C
281.9 2.9
309.8 3.5
294.6 6.7
0.306
0.310
0.315
36.57 2.67
Not measured
36.88 1.61
Fig. 6. X-ray diffraction patterns: (A): Compritol 888 bulk material, (B): freeze dried NLC batch, 0.025% drug loading, (C) freeze dried NLC batch, 0.05% drug loading, and (D):
freeze dried SLN batch, 0.05% drug loading.
449
Fig. 7. Modulated DSC scans; (A): Freeze dried SLN, 0.05% drug loading, (B): freeze
dried NLC, 0.05% drug loading, and (C): freeze dried NLC, 0.025% drug loading.
present in the nanosystem as undissolved material/in the crystalline state, the relatively low drug loading of quercetin in the nanosystems would render it improbable to detect the melting event of
any such fraction using a DSC based technique.
3.9. Release of quercetin from lipid nanosystems
The release of quercetin from the SLN and NLC formulations
compared to a control formulation of quercetin in propylene glycol
solution are shown in Fig. 8. The formulations with 0.05% quercetin
loading were used to obtain a direct comparison of the release of
quercetin from formulations with and without oleic acid. Quercetin from the NLC formulation (with oleic acid) was released at a
faster rate compared to the SLN formulation (without oleic acid).
This is consistent with literature references comparing the release
rates from SLN and NLC formulations (Hu et al., 2005; Souto et al.,
2004). The release prole from both SLN and NLC formulations
were biphasic, with an initial burst release (55% from the NLC formulation compared to 45% from the SLN formulation after 2 h)
followed by controlled release for up to 30 h. Equilibrium was attained within 24 h, which was conrmed by the plateau observed
in the release prole between 24 and 30 h. The incorporation of the
liquid lipid (oleic acid) in the NLC formulation reduced the viscosity of the lipid matrix, leading to faster diffusion and release of the
drug from the NLC system compared to the SLN system that was
composed solely of solid lipids.
Statistical analysis showed signicant differences in the rate of
release of quercetin from the control formulation compared to both
the SLN and NLC formulations (p < 0.05). Also, statistically signicant differences in quercetin release rates were observed between
the SLN and NLC formulations at the earlier time points up to 6 h
(p < 0.05). Beyond 6 h, the differences in release rates between the
SLN and NLC systems were not statistically signicant (p > 0.05).
3.10. Topical delivery of quercetin from lipid nanosystems
In most in vitro permeation studies, the feasibility of topical
delivery of quercetin from the optimized formulation has been
450
the SLN and NLC formulations), with particle size in the micrometer
range, were used as the control formulations. Sampling from the
receptor media was carried out at 2, 4, 6, 8 and 24 h. However, no
quercetin could be detected in the receptor media, indicating the
lack of any transdermal delivery. This observation is consistent with
reports from other studies with quercetin (Vicentini et al., 2008;
Kitagawa et al., 2009), including one study from a chitosanlecithin
based nanoparticle formulation (Tan et al., 2011). The NLC formulation (with oleic acid) showed the highest amount of quercetin retained in the skin at the end of the 24 h experimental period
(Fig. 9). The difference in the amount of quercetin retained in the
skin was not found to be statistically signicant (p > 0.05) between
the NLC and the SLN formulation. However, tighter standard deviation values were observed from the NLC formulation which could
possibly be attributed to the improved physical stability of this formulation compared to the SLN formulation. Statistically signicant
differences (p < 0.05) were observed between the lipid based
451
References
Araujo, J., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., 2010. Optimization
and physicochemical characterization of a triamcinolone acetonide-loaded NLC
for ocular antiangiogenic applications. Int. J. Pharm. 393, 168176.
Bors, W., Heller, W., Michel, C., Saran, M., 1990. Flavonoids as antioxidants:
determination of radical-scavenging efciencies. Methods Enzymol. 186, 343
355.
Casagrande, R., Georgetti, S.R., Verri Jr., W.A., Dorta, D.J., dos Santos, A.C., Fonseca,
M.J., 2006. Protective effect of topical formulations containing quercetin against
UVB-induced oxidative stress in hairless mice. J. Photochem. Photobiol. B 84,
2127.
Chapman, D., 1962. The polymorphism of glycerides. Chem. Rev. 62, 433456.
Chen-yu, G., Chun-fen, Y., Qi-lu, L., Qi, T., Yan-wei, X., Wei-na, L., Guang-xi, Z., 2012.
Development of a quercetin-loaded nanostructured lipid carrier formulation for
topical delivery. Int. J. Pharm. 430, 292298.
Cirri, M., Bragagni, M., Mennini, N., Mura, P., 2012. Development of a new delivery
system consisting in drugin cyclodextrinin nanostructured lipid carriers for
ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 80, 4653.
Das, S., Ng, W.K., Kanaujia, P., Kim, S., Tan, R.B., 2011. Formulation design,
preparation and physicochemical characterizations of solid lipid nanoparticles
containing a hydrophobic drug: effects of process variables. Colloids Surf. B
Biointerfaces 88, 483489.
El Maghraby, G.M., Williams, A.C., Barry, B.W., 2004. Interactions of surfactants
(edge activators) and skin penetration enhancers with liposomes. Int. J. Pharm.
276, 143161.
Epstein, J.H., 1983. Phototoxicity and photoallergy in man. J. Am. Acad. Dermatol. 8,
141147.
Esposito, E., Fantin, M., Marti, M., Drechsler, M., Paccamiccio, L., Mariani, P., Sivieri,
E., Lain, F., Menegatti, E., Morari, M., Cortesi, R., 2008. Solid lipid nanoparticles as
delivery systems for bromocriptine. Pharm. Res. 25, 15211530.
Fang, J.Y., Hwang, T.L., Fang, C.L., Chiu, H.C., 2003. In vitro and in vivo evaluations of
the efcacy and safety of skin permeation enhancers using urbiprofen as a
model drug. Int. J. Pharm. 255, 153166.
Filipe, P., Silva, J.N., Haigle, J., Freitas, J.P., Fernandes, A., Santus, R., Morliere, P., 2005.
Contrasting action of avonoids on phototoxic effects induced in human skin
broblasts by UVA alone or UVA plus cyamemazine, a phototoxic neuroleptic.
Photochem. Photobiol. Sci. 4, 420428.
Francoeur, M.L., Golden, G.M., Potts, R.O., 1990. Oleic acid: its effects on stratum
corneum in relation to (trans)dermal drug delivery. Pharm. Res. 7, 621627.
Freitas, C., Mller, R.H., 1998. Effect of light and temperature on zeta potential and
physical stability in solid lipid nanoparticle (SLN) dispersions. Int. J. Pharm. 168,
221229.
Freitas, C., Mller, R.H., 1999. Correlation between long-term stability of solid lipid
nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm.
Biopharm. 47, 125132.
Golden, G.M., McKie, J.E., Potts, R.O., 1987. Role of stratum corneum lipid uidity in
transdermal drug ux. J. Pharm. Sci. 76, 2528.
Gonzalez, S., Fernandez-Lorente, M., Gilaberte-Calzada, Y., 2008. The latest on skin
photoprotection. Clin. Dermatol. 26, 614626.
Gonzalez-Mira, E., Nikolic, S., Garcia, M.L., Egea, M.A., Souto, E.B., Calpena, A.C.,
2011. Potential use of nanostructured lipid carriers for topical delivery of
urbiprofen. J. Pharm. Sci. 100, 242251.
Goodman, M., Barry, B.W., 1989. Lipid-protein-partitioning (LPP) theory of skin
enhancer activity: nite dose technique. Int. J. Pharm. 57, 2940.
Grabnar, P.A., Kristl, J., 2011. The manufacturing techniques of drug-loaded
polymeric nanoparticles from preformed polymers. J. Microencapsul. 28, 323
335.
Gugler, R., Leschik, M., Dengler, H.J., 1975. Disposition of quercetin in man after
single oral and intravenous doses. Eur. J. Clin. Pharm. 9, 229234.
Hamdani, J., Moes, A.J., Amighi, K., 2003. Physical and thermal characterisation of
precirol and compritol as lipophilic glycerides used for the preparation of
controlled-release matrix pellets. Int. J. Pharm. 260, 4757.
Hu, F.Q., Jiang, S.P., Du, Y.Z., Yuan, H., Ye, Y.Q., Zeng, S., 2005. Preparation and
characterization of stearic acid nanostructured lipid carriers by solvent
diffusion method in an aqueous system. Colloids Surf. B Biointerfaces 45,
167173.
Jenning, V., Gysler, A., Schafer-Korting, M., Gohla, S.H., 2000a. Vitamin A loaded
solid lipid nanoparticles for topical use: occlusive properties and drug targeting
to the upper skin. Eur. J. Pharm. Biopharm. 49, 211218.
Jenning, V., Schafer-Korting, M., Gohla, S., 2000b. Vitamin A-loaded solid lipid
nanoparticles for topical use: drug release properties. J. Control. Release 66,
115126.
Jenning, V., Thunemann, A.F., Gohla, S.H., 2000c. Characterisation of a novel solid
lipid nanoparticle carrier system based on binary mixtures of liquid and solid
lipids. Int. J. Pharm. 199, 167177.
Jensen, L.B., Petersson, K., Nielsen, H.M., 2011. In vitro penetration properties of
solid lipid nanoparticles in intact and barrier-impaired skin. Eur. J. Pharm.
Biopharm. 79, 6875.
Jores, K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C., Mader, K., 2004.
Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded
solid lipid nanoparticles by photon correlation spectroscopy, eld-ow
fractionation and transmission electron microscopy. J. Control. Release 95,
217227.
452
Kitagawa, S., Tanaka, Y., Tanaka, M., Endo, K., Yoshii, A., 2009. Enhanced skin
delivery of quercetin by microemulsion. J. Pharm. Pharmacol. 61, 855860.
Kuo, Y.C., Chung, J.F., 2011. Physicochemical properties of nevirapine-loaded solid
lipid nanoparticles and nanostructured lipid carriers. Colloids Surf. B
Biointerfaces 83, 299306.
Li, H., Zhao, X., Ma, Y., Zhai, G., Li, L., Lou, H., 2009. Enhancement of gastrointestinal
absorption of quercetin by solid lipid nanoparticles. J. Control Release 133, 238
244.
Lombardi Borgia, S., Regehly, M., Sivaramakrishnan, R., Mehnert, W., Korting, H.C.,
Danker, K., Roder, B., Kramer, K.D., Schafer-Korting, M., 2005. Lipid
nanoparticles for skin penetration enhancement-correlation to drug
localization within the particle matrix as determined by uorescence and
parelectric spectroscopy. J. Control. Release 110, 151163.
Luo, Q., Zhao, J., Zhang, X., Pan, W., 2011. Nanostructured lipid carrier (NLC) coated
with chitosan oligosaccharides and its potential use in ocular drug delivery
system. Int. J. Pharm. 403, 185191.
Maia, C.S., Mehnert, W., Schafer-Korting, M., 2000. Solid lipid nanoparticles as drug
carriers for topical glucocorticoids. Int. J. Pharm. 196, 165167.
Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., Muller, R.H., 2011. Lipid nanocarriers
for dermal delivery of lutein: preparation, characterization, stability and
performance. Int. J. Pharm. 414, 267275.
Montenegro, L., Carbone, C., Maniscalco, C., Lambusta, D., Nicolosi, G., Ventura, C.A.,
Puglisi, G., 2007. In vitro evaluation of quercetin-3-O-acyl esters as topical
prodrugs. Int. J. Pharm. 336, 257262.
Moreira, T.S., de Sousa, V.P., Pierre, M.B., 2010. A novel transdermal delivery system
for the anti-inammatory lumiracoxib: inuence of oleic acid on in vitro
percutaneous absorption and in vivo potential cutaneous irritation. AAPS.
Pharm. Sci. Technol. 11, 621629.
Muller, R.H., Radtke, M., Wissing, S.A., 2002. Solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) in cosmetic and dermatological
preparations. Adv. Drug Deliv. Rev. 54 (Suppl 1), S131S155.
Muller, R.H., Petersen, R.D., Hommoss, A., Pardeike, J., 2007. Nanostructured lipid
carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 59, 522530.
Murakami, T., Yoshioka, M., Yumoto, R., Higashi, Y., Shigeki, S., Ikuta, Y., Yata, N.,
1998. Topical delivery of keloid therapeutic drug, tranilast, by combined use of
oleic acid and propylene glycol as a penetration enhancer: evaluation by skin
microdialysis in rats. J. Pharm. Pharmacol. 50, 4954.
Olivella, M.S., Lhez, L., Pappano, N.B., Debattista, N.B., 2007. Effects of
dimethylformamide and L-menthol permeation enhancers on transdermal
delivery of quercetin. Pharm. Dev. Technol. 12, 481484.
Ongpipattanakul, B., Burnette, R.R., Potts, R.O., Francoeur, M.L., 1991. Evidence that
oleic acid exists in a separate phase within stratum corneum lipids. Pharm. Res.
8, 350354.
Pardeike, J., Weber, S., Haber, T., Wagner, J., Zar, H.P., Plank, H., Zimmer, A., 2011.
Development of an itraconazole-loaded nanostructured lipid carrier (NLC)
formulation for pulmonary application. Int. J. Pharm. 419, 329338.
Pourzand, C., Tyrrell, R.M., 1999. Apoptosis, the role of oxidative stress and the
example of solar UV radiation. Photochem. Photobiol. 70, 380390.
Saija, A., Scalese, M., Lanza, M., Marzullo, D., Bonina, F., Castelli, F., 1995. Flavonoids
as antioxidant agents: importance of their interaction with biomembranes. Free
Radical Biol. Med. 19, 481486.
Schafer-Korting, M., Mehnert, W., Korting, H.C., 2007. Lipid nanoparticles for
improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 59,
427443.
Siekmann, B., Westesen, K., 1994. Melt-homogenized solid lipid nanoparticles
stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size
determination. Pharm. Pharmacol. Lett. 3, 194197.
Silva, A.C., Santos, D., Ferreira, D.C., Souto, E.B., 2009. Minoxidil-loaded
nanostructured lipid carriers (NLC): characterization and rheological
behaviour of topical formulations. Pharmazie 64, 177182.
Sim, G.S., Lee, B.C., Cho, H.S., Lee, J.W., Kim, J.H., Lee, D.H., Kim, J.H., Pyo, H.B., Moon,
D.C., Oh, K.W., Yun, Y.P., Hong, J.T., 2007. Structure activity relationship of
antioxidative property of avonoids and inhibitory effect on matrix
metalloproteinase activity in UVA-irradiated human dermal broblast. Arch.
Pharm. Res. 30, 290298.
Sintov, A., Zeevi, A., Uzan, R., Nyska, A., 1999. Inuence of pharmaceutical gel
vehicles containing oleic acid/sodium oleate combinations on hairless mouse
skin, a histological evaluation. Eur. J. Pharm. Biopharm. 47, 299303.
Song, C.K., Balakrishnan, P., Shim, C.K., Chung, S.J., Chong, S., Kim, D.D., 2012. A novel
vesicular carrier, transethosome, for enhanced skin delivery of voriconazole:
characterization and in vitro/in vivo evaluation. Colloids Surf. B Biointerfaces
92, 299304.
Souto, E.B., Wissing, S.A., Barbosa, C.M., Muller, R.H., 2004. Development of a
controlled release formulation based on SLN and NLC for topical clotrimazole
delivery. Int. J. Pharm. 278, 7177.
Tan, Q., Liu, W., Guo, C., Zhai, G., 2011. Preparation and evaluation of quercetinloaded lecithinchitosan nanoparticles for topical delivery. Int. J.
Nanomedicine. 6, 16211630.
Tanojo, H., Boelsma, E., Junginger, H.E., Ponec, M., Boddec, H.E., 1999. In vivo human
skin permeability enhancement by oleic acid: a laser doppler velocimetry study.
J. Control Release 58, 97104.
Teeranachaideekul, V., Souto, E.B., Junyaprasert, V.B., Muller, R.H., 2007. Cetyl
palmitate-based NLC for topical delivery of coenzyme Q(10) development,
physicochemical characterization and in vitro release studies. Eur. J. Pharm.
Biopharm. 67, 141148.
Teeranachaideekul, V., Boonme, P., Souto, E.B., Muller, R.H., Junyaprasert, V.B., 2008.
Inuence of oil content on physicochemical properties and skin distribution of
Nile red-loaded NLC. J. Control. Release 128, 134141.
Tiwari, R., Pathak, K., 2011. Nanostructured lipid carrier versus solid lipid
nanoparticles of simvastatin: comparative analysis of characteristics,
pharmacokinetics and tissue uptake. Int. J. Pharm. 415, 232243.
Touitou, E., Godin, B., Karl, Y., Bujanover, S., Becker, Y., 2002. Oleic acid, a skin
penetration enhancer, affects langerhans cells and corneocytes. J. Control.
Release 80, 17.
Vicentini, F.T., Simi, T.R., Del Ciampo, J.O., Wolga, N.O., Pitol, D.L., Iyomasa, M.M.,
Bentley, M.V., Fonseca, M.J., 2008. Quercetin in w/o microemulsion: in vitro and
in vivo skin penetration and efcacy against UVB-induced skin damages
evaluated in vivo. Eur. J. Pharm. Biopharm. 69, 948957.
Yamane, M.A., Williams, A.C., Barry, B.W., 1995. Effects of terpenes and oleic acid as
skin penetration enhancers towards 5-uorouracil as assessed with time;
permeation, partitioning and differential scanning calorimetry. Int. J. Pharm.
116, 237251.
Ying, X.Y., Du, Y.Z., Chen, W.W., Yuan, H., Hu, F.Q., 2008. Preparation and
characterization of modied lipid nanoparticles for doxorubicin controlled
release. Pharmazie 63, 878882.
You, J., Wan, F., de, C.F., Sun, Y., Du, Y.Z., Hu, F.Q., 2007. Preparation and
characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int. J.
Pharm. 343, 270276.
Yu, A., Guo, C., Zhou, Y., Cao, F., Zhu, W., Sun, M., Zhai, G., 2010. Skin irritation and
the inhibition effect on HSV-1 in vivo of penciclovir-loaded microemulsion. Int.
Immunopharmacol. 10, 13051309.
Zhang, J., Smith, E., 2011. Percutaneous permeation of betamethasone 17-valerate
incorporated in lipid nanoparticles. J. Pharm. Sci. 100, 896903.